Loading...
XSTO
CANTA
Market cap51mUSD
Jul 10, Last price  
1.99SEK
1D
-2.93%
1Q
-49.23%
Jan 2017
-68.52%
IPO
-76.57%
Name

Cantargia AB

Chart & Performance

D1W1MN
XSTO:CANTA chart
P/E
3.37
P/S
1.56
EPS
0.59
Div Yield, %
—
Shrs. gr., 5y
18.28%
Rev. gr., 5y
%
Revenues
317m
00000000000000316,702,000
Net income
147m
P
-3,389,000-3,465,000-7,946,000-8,370,000-17,190,000-44,680,000-60,253,000-91,160,000-110,809,000-173,085,000-366,504,000-371,814,000-280,027,000-161,654,000146,974,000
CFO
150m
P
-2,915,391-3,779,484-8,262,4866,897,877-30,277,000-39,528,000-41,103,000-104,686,000-111,254,000-156,387,000-346,445,000-358,915,000-286,664,000-162,752,000150,135,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
URL
https://cantargia.com/
IPO date
Mar 17, 2015
Employees
24
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT